STOCK TITAN
  1. Home
  2. News
  3. SPRC

SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.

SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.

The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.

In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.

SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.

The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.

Latest News:

  • March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
  • March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
  • March 14, 2024: First patient dosed in SCI-210 ASD trial.
  • March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
  • March 27, 2024: Clearmind partnership leads to multiple new patent applications.
  • May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
News

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

Rhea-AI Summary
SciSparc announces MitoCareX Bio's successful identification of potential anti-cancer small molecules through advanced drug discovery platform and in-vitro screening systems, leading to the development of a predictive AI model for more efficient drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
News

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

Rhea-AI Summary
SciSparc (Nasdaq: SPRC) secures a patent for its core technology combining cannabinoids and n-acylethanolamines from the Canadian Intellectual Property Office. The patent aims to enhance the safety of cannabinoids with low dosages while maintaining therapeutic benefits, supporting the company's innovative technologies for central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
News

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) has dosed the first patient in a clinical trial for Autism Spectrum Disorder in pediatric patients. The trial is for SCI-210 at Soroka Medical Center, marking a crucial advancement in treating rare diseases of the central nervous system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
clinical trial
News

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces MitoCareX Bio's progress in utilizing a predictive AI model to identify potential anti-cancer treatments. MitoCareX screened millions of small molecules, confirming anti-cancer activity through in-vitro testing. The company aims to enhance drug discovery efficiency by developing a predictive AI model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
-
News

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

Rhea-AI Summary
SciSparc Ltd. announces enrollment of the first patient in a clinical trial for SCI-210, a treatment for children with autism spectrum disorder. The company aims to address the unmet need for efficient and safe treatments in this area.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags
clinical trial
-
News

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces the completion of the granting and validation process for its core-technology patent covering combinations of cannabinoids and n-acylethanolamines in certain European countries. This patent enhances the safety of cannabinoids, maintaining therapeutic benefits with low dosages of active components. The Patent was granted and validated in multiple European countries, supporting SciSparc's innovative technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
News

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) receives patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment from the Canadian Intellectual Property Office. The global opioid market is valued at $22.8 billion in 2022 and is expected to grow at a CAGR of 1.4% from 2023 to 2030. SciSparc aims to improve the therapeutic effect of opiates in lower doses to reduce their addictive potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
News

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) has successfully completed manufacturing and delivering its SCI-210 treatment for a clinical trial on pediatric patients with Autism Spectrum Disorder (ASD). The trial will evaluate the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy, with primary endpoints including the Aberrant Behavior Checklist-Community (ABC-C) and Clinical Global Impressions-Improvement (CGI-I) scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
clinical trial
-
News

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Rhea-AI Summary
SciSparc Ltd. announces collaboration with Clearmind Medicine Inc. for patent applications on novel psychedelic-derived therapeutics, focusing on mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
partnership
News

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces collaboration with Clearmind Medicine Inc. to develop novel psychedelic-derived therapeutics. Clearmind files three patent applications for proprietary combinations of LSD, psilocybin, DMT, and PEA with CannAmide™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.52%
Tags
none

FAQ

What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?

The current stock price of SciSparc Ltd. Ordinary Shares (SPRC) is $0.5879 as of January 23, 2025.

What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?

The market cap of SciSparc Ltd. Ordinary Shares (SPRC) is approximately 6.6M.

What does SciSparc Ltd. do?

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.

What are SciSparc's main drug development programs?

SciSparc's main programs include SCI-110 for Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for ASD and status epilepticus.

What recent achievements has SciSparc announced?

Recent achievements include enrolling the first patient in the SCI-210 ASD trial, obtaining a Canadian patent, and expanding partnerships with MitoCareX Bio and Clearmind.

What products does SciSparc offer online?

SciSparc's subsidiary sells hemp-based products like gummies, oils, capsules, and creams on Amazon Marketplace.

Where is SciSparc Ltd. based?

SciSparc Ltd. is based in Tel Aviv, Israel.

Is SciSparc involved in cancer research?

Yes, through its venture MitoCareX Bio, SciSparc is involved in cancer drug discovery targeting mitochondrial SLC25 proteins.

What patents has SciSparc recently secured?

SciSparc has recently secured patents in the U.S., Canada, and Europe for cannabinoid compositions and antimicrobial methods.

Who leads SciSparc Ltd.?

SciSparc Ltd. is led by a team of experienced senior executives and scientists.

What is SCI-210?

SCI-210 is a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for Autism Spectrum Disorder and status epilepticus.

What is the significance of SciSparc's new patents?

The new patents strengthen SciSparc's intellectual property portfolio and enhance its position in the global pharmaceutical market.
Stock SPRC logo
SciSparc Ltd. Ordinary Shares

Nasdaq:SPRC

SPRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SPRC Stock Data

6.59M
10.83M
0%
1.73%
1.5%
Biotechnology
Healthcare
Link
United States of America
Tel Aviv